logo
Malcolm Potts, Irreverent Evangelist for Contraception, Dies at 90

Malcolm Potts, Irreverent Evangelist for Contraception, Dies at 90

New York Times15-05-2025
Malcolm Potts, a physician, reproductive scientist and contraceptive evangelist who helped develop and promote the device most frequently used to perform surgical abortions, and who spent more than half a century directing programs that provide reproductive health services to women in developing countries, died on April 25 at his home in Berkeley, Calif. He was 90.
The cause was Alzheimer's disease, said his stepdaughter, Madison Iler.
Although he didn't identify himself as such, Dr. Potts was essentially a neo-Malthusian. Like Thomas Robert Malthus, the economist of the late 18th and early 19th centuries. he saw population control as critical to preventing war, famine and environmental collapse, particularly in Africa, where for decades he oversaw women's health programs, first as medical director of the International Planned Parenthood Federation and then as president of Family Health International, another global organization. He felt that women's ability to control their own reproductive lives was crucial to that aim — an enormous challenge in the conservative countries he served.
'Malcolm felt we were heading for catastrophe if we didn't do a better job in family planning,' said Stefano Bertozzi, a former dean at the University of California, Berkeley School of Public Health, where Dr. Potts held an endowed chair in population and family planning. The two met when they were working on H.I.V. prevention in Africa for different organizations.
'He was a ferocious ally for women having unfettered access to the tools they needed to manage their own fertility,' Dr. Bertozzi said in an interview.
The British-born Dr. Potts was rumpled, tweedy and irreverent. He was of a generation that did not pander to political correctness, and he had a collection of ties printed with condoms. He was also one of Berkeley's most popular professors. His classes on human sexuality, at which he dispensed policy points, naughty anecdotes and common sense, were filled to overflowing. Dr. Bertozzi called him the Bernie Sanders of Berkeley.
'He was the biggest feminist I ever met — and the most unlikely,' said Alisha Graves, a public-health policy expert and former student of Dr. Potts's. Together the two of them founded OASIS (the initials stand for Organizing to Advance Solutions in the Sahel), an organization that serves women in the Sahel, a region just below the Sahara that encompasses 10 countries and has been battered by climate change, poverty and high rates of fertility — as well as its terrible byproduct, maternal mortality.
Dr. Potts's focus was global, but his first brush with the fallout from unwanted pregnancies happened at home.
A newly minted obstetrician, he was fresh out of medical school at the University of Cambridge when he was posted to a busy hospital in North London. There, he regularly treated women suffering from incomplete abortions — meaning that they were still pregnant, but losing blood.
It was the early 1960s, abortion was not yet legal in England, and, Dr. Potts said, the experience was an epiphany.
He opened a clinic to provide contraception to single women and vasectomies to men. And he joined a lobbying group of medical professionals working for the legalization of abortion in Britain, which happened in 1967.
Dr. Potts became a well-known booster of oral contraceptives; he once told a newspaper reporter that the Pill was so safe, he would give it to his 2-year-old daughter. He famously appeared on David Frost's late-1960s talk show, 'The Frost Programme,' to debate the merits of oral contraceptives with a conservative gynecologist. The gynecologist averred that they were so dangerous, he would prescribe them only to prostitutes. Dr. Potts responded by pouring a bag of rice onto a table and picking out two grains, to indicate the percentage of women at risk of death from taking birth control pills. He then counted out 27 grains to illustrate the percentage of women at risk of dying from an unintended pregnancy.
'It would be a service to mankind if the Pill were available in vending machines and cigarettes were placed on prescription,' Dr. Potts told Reader's Digest in 1969. (It was a sign of the times that cigarettes were then sold in vending machines, like candy.)
In 1968, Dr. Potts became the medical director of the International Planned Parenthood Federation. In that position, he saw firsthand how the low status of women in poor countries led to harsh outcomes in their reproductive health.
He began to research ways to provide safe abortions in places where medical care was delivered in less-than-optimal conditions. He read about Harvey Karman, an eccentric activist and psychologist in training at the University of California, Los Angeles, who had come up with a way of performing abortions that was safer and less painful than what was then the more frequently used method, dilation and curettage. Vacuum extraction, as the technique is called, is now the most common surgical procedure for ending a pregnancy.
Dr. Potts sought out Mr. Karman, and together they refined the device he invented to perform vacuum extraction. They wrote about it for The Lancet, the British medical journal, whose editors were unaware that Dr. Potts's co-author was not a medical doctor. Dr. Potts received a grant from the United States Agency for International Development to provide the device to International Planned Parenthood Federation clinics around the world.
In 1972, the two men brought the device to Bangladesh, where they were part of a team of medical professionals invited by the government to perform abortions on rape victims and to train local doctors in the procedure. (Some 1,500 women and girls, many as young as 10 years old, had been raped by Pakistani soldiers during the Indo-Pakistan war of 1971, when Bangladesh won its independence.)
In India, Dr. Potts traveled to Mumbai (then known as Bombay) to provide vasectomies; he set up a clinic on a train station platform because men there were fearful of hospitals. In Thailand, he organized a community-based distribution system of birth control pills and condoms, training market vendors, shopkeepers, schoolteachers and one undertaker to dispense them properly.
A decade ago, Dr. Potts started a company called Cadence with Nap Hosang, an obstetrician who was his colleague at Berkeley, and Samantha Miller, a pharmaceutical industry veteran, to produce a birth control pill that could be sold without a prescription. After years of holdups by the Food and Drug Administration, exacerbated in recent months by layoffs at the agency, it has yet to be approved.
Zena, as it's called, is a combination progesterone-estrogen pill that carries a low risk of blood clots. (An online questionnaire, should the pill receive the go-ahead, would evaluate each woman's risk.)
The company has been more successful with its Morning After Pill, which is sold online, in convenience stores like 7-Eleven and in vending machines on college campuses.
David Malcolm Potts was born on Jan. 8, 1935, in Sunderland, England, the youngest of three sons of Kathleen (Cole) Potts and Ronald Windle Potts. He grew up in Newcastle and attended Cambridge, where he earned his medical degree and a Ph.D. in embryology.
Dr. Potts was married four times. His marriages to Dera Joyce Cook and Caroline Merula Deys ended in divorce. His third wife, Marcia Jaffe Potts, died in 1993. His fourth wife, Martha Madison Campbell, died in 2022.
In addition to Ms. Iler, his stepdaughter, Dr. Potts is survived by a son, Oliver Macdonald, from his first marriage; a daughter, Sarah Deyes Longlands, and a son, Henry Potts, from his second; a daughter, Sandra Potts Jaffe, from his third; two stepsons, Douglas Iler and Bruce Iler; seven grandchildren; and four great-grandchildren.
Dr. Potts was the author of a number of books — not only practical textbooks on contraception, but also quirkier fare, including 'Queen Victoria's Gene: Haemophilia and the Royal Family' (1995), written with his brother William, which suggested that Queen Victoria had been illegitimate. They noted that none of her ancestors had possessed the genetic mutation for hemophilia, which she famously passed along to royalty throughout Europe. Therefore, they argued, her father could not have been Prince Edward.
When the book came out, Dr. Potts told The Sunday Times of London that he thought Queen Victoria's body should be exhumed for DNA testing to settle the matter. A spokesman for the royal family responded, 'I don't think there's been any attempt ever to dig up members of the royal family.'
'Sex and War: How Biology Explains Warfare and Terrorism and Offers a Path to a Safer World' (2008), which Dr. Potts wrote with Thomas Hayden, a journalist, explored what they called the male predisposition to team aggression, tracing it from prehistory and primatology to current horrors.
Educating women and girls to increase the number of women in leadership roles was one of their suggestions for a way to 'help make peace break out.'
'Peace needs strong allies in order to persist,' they wrote, 'and the ally that has been the most consistently overlooked is the one that makes up slightly over half the human race — women.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UCLA loses federal research funding in administration's ongoing fight with top universities
UCLA loses federal research funding in administration's ongoing fight with top universities

CNN

timean hour ago

  • CNN

UCLA loses federal research funding in administration's ongoing fight with top universities

UCLA is the latest major institution of higher learning to see promised research funding snatched away by the Trump administration, the university's leader said in an open letter to students and faculty Thursday. 'This is not only a loss to the researchers who rely on critical grants,' wrote Chancellor Julio Frenk. 'It is a loss for Americans across the nation whose work, health, and future depend on the groundbreaking work we do.' Grants from the National Science Foundation and the National Institutes of Health are included in the suspensions, Frenk said, but did not provide an amount of how much funding is in peril. The Los Angeles Times reported that roughly $200 million in grants awarded to UCLA are being suspended, citing a partial list of suspended grants provided to them by a source. A spokesperson for the National Science Foundation declined to provide specific figures, saying grant awards are being suspended 'because they are not in alignment with current NSF priorities and/or programmatic goals.' 'We will not fund institutions that promote antisemitism,' said a spokesperson for the Department of Health and Human Services, which includes the National Institutes of Health. 'We will use every tool we have to ensure institutions follow the law.' The Trump administration has repeatedly cited antisemitism – especially in the context of contentious pro-Gaza protests on campuses – as a reason to deny promised funds to universities, including Harvard and Columbia. Harvard is fighting the funding decisions in court, while Columbia agreed to a settlement with the government that restored its grants. The funding cut comes days after the Justice Department's Civil Rights Division announced it found UCLA in violation of federal law by 'acting with deliberate indifference in creating a hostile educational environment for Jewish and Israeli students.' While the formal notice to UCLA said the federal government 'now seeks to enter into a voluntary resolution agreement,' Attorney General Pam Bondi sounded less conciliatory. 'DOJ will force UCLA to pay a heavy price for putting Jewish Americans at risk and continue our ongoing investigations into other campuses in the UC system,' Bondi said in a statement. It is not just the Trump administration that has tangled with UCLA over charges of antisemitism. A group of Jewish students filed suit against the university last June, saying the school allowed discrimination against Jews to flourish following Israel's military operation in Gaza in response to the October 7 attacks. The lawsuit said UCLA leaders waited days before responding to a group of pro-Palestinian protesters that refused to allow students to enter campus unless they agreed to 'a statement pledging their allegiance to the activists' views.' UCLA settled the lawsuit earlier this week for $6.45 million, with more than $2 million of the total going to designated 'organizations that combat antisemitism and support the UCLA Jewish community.' UCLA also agreed it is prohibited from 'knowingly allowing or facilitating the exclusion of Jewish students, faculty, and/or staff' from university programs and activities.

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Yahoo

time2 hours ago

  • Yahoo

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two refills per year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in approximately 95% of patients Susvimo was well tolerated over five years and has a well-characterised safety profile Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States. 'These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with nAMD, the leading cause of vision loss in people over age 60,' said Levi Garraway, MD, PhD, Roche's chief medical officer and head of Global Product Development. 'These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.' 'People with nAMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections,' said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. 'Continuous delivery of treatment with Susvimo may preserve vision in patients with nAMD for longer in real-world clinical use than IVT injections.' In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132). Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort. The cohort of people who entered the Portal study from Archway is the largest cohort of people with nAMD to be followed prospectively and continuously for five years in a clinical study.1 Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss. About the Archway study and its open-label extension study (Portal)1,2Archway (NCT03677934) was a randomised, multicentre, open-label phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with nAMD. Patients were randomized 3:2 to Susvimo (n = 248) or IVT ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in centre point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing. About neovascular age-related macular degenerationAge-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading.3 Neovascular or 'wet' AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.4,5 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.5 Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.3,6,7 About Susvimo® (Port Delivery System with ranibizumab)Approved in the United States by the Food and Drug Administration (FDA) for nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR), Susvimo is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure.8,9 Susvimo continuously delivers a customised formulation of ranibizumab over time.8,9 Ranibizumab is a VEGF inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.8-10The customised formulation of ranibizumab delivered by Susvimo is different from the ranibizumab IVT injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved to treat nAMD and other retinal diseases.11 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. *Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. References[1] Kitchens J, et al. Five Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS. Presented at: The American Society of Retina Specialists (ASRS) 2025 Annual Meeting; 2025 August 01; Long Beach, California, United States.[2] Regillo C, et al. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023;130(7):735-747.[3] Bright Focus Foundation. Age-related macular degeneration (AMD): facts & figures. [Internet; cited July 2025]. Available from: [4] Pennington KL, et al. Epidemiology of AMD: associations with cardiovascular disease phenotypes and lipid factors. Eye and Vision. 2016;3:34.[5] Little K, et al. Myofibroblasts in macular fibrosis secondary to nAMD - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283-91.[6] Connolly E, et al. Prevalence of AMD associated genetic risk factors and four-year progression data in the Irish population. British Journal of Ophthalmology. 2018 Feb;102:1691-95.[7] Wong WL, et al. Global prevalence of AMD and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014 Feb;2:106-16.[8] US Food and Drug Administration (FDA). Highlights of prescribing information, Susvimo. 2021. [Internet; cited July 2025]. Available from: [9] Holekamp N, et al. Archway randomised phase III trial of the PDS with ranibizumab for neovascular age-related macular degeneration (nAMD). Ophthalmology. 2021.[10] Heier JS, et al. The angiopoietin/tie pathway in retinal vascular diseases: A review. The Journal of Retinal and Vitreous Diseases. 2021;41:1-19.[11] US FDA. Highlights of prescribing information, Lucentis. 2012. [Internet; cited April 2025]. Available from: [12] US FDA. Highlights of prescribing information, Vabysmo. 2024. [Internet; cited April 2025]. Available from: [13] European Medicines Agency. Summary of product characteristics, Vabysmo. [Internet; cited April 2025]. Available from: Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media Investor Release Susvimo Archway study english

States Sue Over Trump Efforts to End Pediatric Transgender Medical Care
States Sue Over Trump Efforts to End Pediatric Transgender Medical Care

New York Times

time3 hours ago

  • New York Times

States Sue Over Trump Efforts to End Pediatric Transgender Medical Care

A coalition of states led by Democrats, including New York and California, sued Friday to stop the Trump administration from investigating doctors and hospitals who provide children with medical treatments for gender transition. The lawsuit, filed in Federal District Court in Massachusetts, comes amid escalating efforts by the federal government to put an end to the availability of puberty blockers, hormones and gender-related surgeries for transgender adolescents. In the past two months, the F.B.I. has asked the public to call its tip line about doctors 'who mutilate' children 'under the guise of gender-affirming care.' The Justice Department sent more than 20 subpoenas to doctors and clinics that perform transgender medical procedures on minors, demanding confidential patient information. And the Federal Trade Commission is examining whether 'practitioners of 'gender-affirming care' may be actively deceiving consumers' by making unsubstantiated claims about the effectiveness of such care, or by omitting warnings about risks to pediatric patients. Some medical experts have concerns about the long-term side effects of puberty blockers and hormones on brain development, bone density and fertility. Federal agencies served at least two subpoenas to major New York hospital systems in recent weeks — Mount Sinai Health and NYU Langone Health — as part of the inquiries into pediatric transgender medicine, according to people familiar with the matter who spoke on the condition of anonymity because they were not authorized to disclose subpoenas or had been told about their existence in confidence. Representatives for Mount Sinai and NYU Langone declined to comment. The Justice Department did not immediately respond to a request for comment. The lawsuit, filed by attorneys general for 15 states and the governor of Pennsylvania, asks the federal court to declare that the government policies that prompted the investigations into pediatric transgender care were unlawful and must not be enforced. The lawsuit argues that the Justice Department's actions 'reflect an unconstitutional attempt to infringe on the states' power to regulate medicine.' Want all of The Times? Subscribe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store